Latozinemab clinical trials
Also written AL001.
How each study uses latozinemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the latozinemab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Alector Inc. (4) · Alzamend Neuro, Inc. (3) · Beijing Anlong Biopharmaceutical Co., Ltd. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test latozinemab.
Studies
Open first, then newest update. How each study uses latozinemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDNot yet recruitingPhase 2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339Written as AL-001
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderActive, not recruitingPhase 1/2Alzamend Neuro, Inc.NCT07540338Written as AL001
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult SubjectsCompletedPhase 1Alzamend Neuro, Inc.NCT06921590Written as AL001
- Continuation Study for LatozinemabTerminatedPhase 3Alector Inc.NCT06111014Written as Latozinemab
- A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)CompletedPhase 2Alector Inc.NCT03987295Written as AL001
- A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSTerminatedPhase 2Alector Inc.NCT05053035Written as AL001
- Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult SubjectsCompletedPhase 1/2Alzamend Neuro, Inc.NCT05363293Written as AL001
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMDActive, not recruitingPhase 1/2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06707753Written as AL-001
- A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationCompletedPhase 1Alector Inc.NCT03636204Written as AL001
Codes
What other systems call latozinemab · ClinicalTrials.gg INT016858
- UNII (FDA) IKT0XSS2XBLATOZINEMABOne source FDA
- NCI Thesaurus C179098LatozinemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IKT0XSS2XB | LATOZINEMAB | One source FDA |
| NCI Thesaurus | C179098 | Latozinemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.